The obligations of marketing authorisation holders laid down in Article 106a(1) of Directive 2001/83/EC, and the obligations of the Member States, the Agency and the Commission laid down in paragraphs 2, 3 and 4 of that Article shall apply to the safety announcements referred to in point (e) of Article 57(1) of this Regulation concerning medicinal products for human use authorised in accordance with this Regulation.
Art. 22 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…
Commission Regulation (EC) No 658/2007 of 14 June 2007 concerning financial penalties fo…1Law
… се уведомява Агенцията за такива съобщения, както е предвидено в член 22 от Регламент (ЕО) № 726/2004 във връзка с член 106а, параграф 1 от …
Judgment of the Court (Grand Chamber) of 23 January 2018. F. Hoffmann-La Roche Ltd and Others v Autorità Garante della Concorrenza e del MerDecision
Article 22 of that regulation provided: ‘The [EMA], acting in close cooperation with the national pharmacovigilance systems established in accordance with Article 102 of Directive 2001/83/EC, shall receive all relevant information …
23 Jan 2018 · 62016CJ0179
Commission Regulation (EU) No 488/2012 of 8 June 2012 amending Regulation (EC) No 658/20…1Law
… се уведомява Агенцията за такива съобщения, както е предвидено в член 22 от Регламент (ЕО) № 726/2004 във връзка с член 106а, параграф 1 от …
Opinion of Advocate General Saugmandsgaard Øe delivered on 25 July 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and OthersDecision
Furthermore, Articles 21 to 29 of that regulation provide for a system of pharmacovigilance for the medicinal products authorised at EU level.
25 Jul 2018 · 62017CC0029
Commission Regulation (EU) No 488/2012 of 8 June 2012 amending Regulation (EC) No 658/20…1Law
… concerns are presented objectively and are not misleading and to notify them to the Agency, as provided for in Article 22 of Regulation (EC) No 726/2004 read together with Article 106a(1) of Directive 2001/83/EC; the obligation to comply …
Judgment of the Court (First Chamber) of 21 November 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and Others.Decision
Articles 25, 25a et 26 of Regulation No 726/2004 read as follows: ‘Article 25 The Agency shall, in collaboration with the Member States, develop standard web-based structured forms for the reporting of suspected adverse reactions by …
21 Nov 2018 · 62017CJ0029
Commission Regulation (EC) No 658/2007 of 14 June 2007 concerning financial penalties fo…1Law
… concerns are presented objectively and are not misleading and to notify them to the Agency, as provided for in Article 22 of Regulation (EC) No 726/2004 read together with Article 106a(1) of Directive 2001/83/EC; the obligation to comply …
Changed on 2 Jul 2012
The Agency, acting in close cooperation with the national pharmacovigilance systems established in accordance with obligations of marketing authorisation holders laid down in Article 102106a(1) of Directive 2001/83/EC, shall receive all relevant information concerning suspected adverse reactions to medicinal products for human use which have been authorised by the Community in accordance with this Regulation. Where appropriateand the obligations of the Member States, the Committee for Medicinal Products for Human Use shall, in accordance with Article 5 of this Regulation, draw up opinions on the measures necessary. These opinions Agency and the Commission laid down in paragraphs 2, 3 and 4 of that Article shall be made publicly accessible.
The measures referred to in the first paragraph may include amendments to the marketing authorisation granted in accordance with Article 10. They shall be adopted in accordance with the procedure apply to the safety announcements referred to in Article 87(3).
The holder of the marketing authorisation and the competent authorities of Member States shall ensure that all relevant information point (e) of Article 57(1) of this Regulation concerning suspected adverse reactions to the medicinal products authorised under this Regulation are brought to the attention of the Agency for human use authorised in accordance with the provisions of this Regulation. Patients shall be encouraged to communicate any adverse reaction to health-care professionals.
- 2 Jul 2012 – todayin force
- 31 Mar 2004 – 2 Jul 2012earlier wording